Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Windlas Biotech Ltd

WINDLAS.NS ✓ COMPLIANTFree checks used up today ☆ Track — members

NSE · Healthcare · Pharmaceuticals ·

India Micro Cap Analyst: N/A

Last Close

$9.20

▼ -5.12%

Market Cap $189.93M · Vol 55.28K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

28.12

FWD: N/A

Market Cap

$189.93M

Micro Cap

Div Yield

0.72%

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

34.47

Momentum

Beta

0.49

vs Market

52W High

$12.42

26.42% below

52W Low

$7.33

21.72% above

Volume

55.28K

Avg 80.25K

P/B

2.68

Price-to-book

ROE

N/A

Return on equity

Free Float

33.78%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Windlas Biotech Ltd (WINDLAS.NS) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does WINDLAS.NS pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+0.39%

-19.72%

+1.88%

+2.85%

YTD

+10.19%

-7.48%

+128.80%

+184.08%

Financials & Valuation

TTM · Annual

Total Revenue	$96.74M
Net Income	$7.11M
Revenue Growth (YoY)	+18.09%
Gross Margin	31.84%
Operating Margin	8.18%
Net Profit Margin	7.35%
ROE	N/A
ROA · ROIC	10.43% · 12.14%

P/E Ratio	28.12
Forward P/E (FY1)	N/A
PEG Ratio	2.99
P/S	1.74
P/B	2.68
P/FCF	46.55
EPS Growth	N/A
Outstanding Shares	20.64M

Technical Indicators

50-Day SMA	$10.69
200-Day SMA	$9.12
RSI (14)	34.47
Beta	0.49
52-Week High	$12.42
52-Week Low	$7.33

Volume Today	55.28K
Avg Daily Volume (30D)	80.25K
Relative Volume	0.69x
Volatility (10D)	40.87
Volatility (30D)	37.31
Free Float	33.78%

Analyst Consensus

N/A

Current Price $9.20

Mean Target N/A

52W Low$7.33 52W High$12.42

Current

Target

$7.33 $12.42

Current Analyst target

· 0 analysts

Identifiers

ExchangeNSE

FIGIBBG009XQMZ68

ISININE0H5O01029

CountryIndia

Sub-IndustryPharmaceuticals (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeFULLPAID Fully Paid Ordinary

Similar Halal Stocks

LLY Eli Lilly and Company +3.19% JNJ Johnson & Johnson -0.73% ABBV AbbVie Inc. +1.41% NVS Novartis AG -0.19% NOVN.S Novartis AG +1.12%

Company Profile

Windlas Biotech Limited is a domestic pharmaceutical formulations contract development and manufacturing organization (CDMO). Its portfolio of CDMO solutions includes product development, licensing, and commercial manufacturing of complex drugs and dosage forms. Its product development and manufacturing capabilities in complex generic products by developing products, including alternate dosages, such as, medicated mouth sprays; coating technologies, including, pellet coating using bottom spray, API coating, pH dependent coating and nanosized crystals; nutraceuticals dosages, including, biscuits, protein powder, supplements, chocolate bars and malt based foods, and ayurvedic products, such as wellness products, hair oils and cough syrups. Its four fungible, Schedule-M compliant OSD/OLD manufacturing facilities are located in Dehradun, Uttarakhand, India. It specializes in manufacturing formulations, solid pharmaceutical dosage forms, liquid pharmaceutical dosage forms and injectables.